Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Targeted Therapy × olutasidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 3 Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Chronic 2 Targeted Therapy 1 Spinal Cord Neoplasms 1 Oligodendroglioma 1 Myeloproliferative Disorders 1 Myeloid Malignancies 1 Glioma 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

venetoclax 1 ruxolitinib 1 olutasidenib 1 gilteritinib 1 Cytarabine 1 Cladribine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07032727 2025-12-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

M.D. Anderson Cancer Center

Phase 2 Recruiting

Targeted Therapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡